Game changer:How Janus kinase inhibitors are reshaping the landscape of ulcerative colitis mana  

作　　者：Antonio M Caballero-Mateos Guillermo Arturo Cañadas-de la Fuente 

机构地区：[1]Department of Gastroenterology and Hepatology,San Cecilio University Hospital,Granada 18014,Spain [2]Department of Nursing,Faculty of Health Sciences,University of Granada,Granada 18004,Spain

出　　处：《World Journal of Gastroenterology》2024年第35期3942-3953,共12页世界胃肠病学杂志（英文版）

摘　　要：Recent advancements in the treatment landscape of ulcerative colitis(UC)have ushered in a new era of possibilities,particularly with the introduction of Janus kinase(JAK)-signal transducer and activator of transcription inhibitors.These novel agents offer a paradigm shift in UC management by targeting key signaling pathways involved in inflammatory processes.With approved JAK inhibitors(JAKis),such as tofacitinib,filgotinib,and upadacitinib,clinicians now have powerful tools to modulate immune responses and gene expression,potentially revolutionizing the treatment algorithm for UC.Clinical trials have demonstrated the efficacy of JAKis in inducing and maintaining remission,presenting viable options for patients who have failed conventional therapies.Real-world data support the use of JAKis not only as first-line treatments but also in subsequent lines of therapy,particularly in patients with aggressive disease phenotypes or refractory to biologic agents.The rapid onset of action and potency of JAKis have broadened the possibilities in the management strategies of UC,offering timely relief for patients with active disease and facilitating personalized treatment approaches.Despite safety concerns,including cardiovascular risks and infections,ongoing research and post-marketing surveillance will continue to refine our understanding of the risk-benefit profile of JAKis in UC management.

关 键 词：Ulcerative colitis Janus kinase inhibitors Filgotinib Tofacitinib Upadacitinib 

分 类 号：R574.62[医药卫生—消化系统]